A digital platform for the design of patient-centric supply chains

Abstract

Chimeric Antigen Receptor (CAR) T cell therapies have received increasing attention, showing promising results in the treatment of acute lymphoblastic leukaemia and aggressive B cell lymphoma. Unlike typical cancer treatments, autologous CAR T cell therapies are patient-specific; this makes them a unique therapeutic to manufacture and distribute. In this work, we focus on the development of a computer modelling tool to assist the design and assessment of supply chain structures that can reliably and cost-efficiently deliver autologous CAR T cell therapies. We focus on four demand scales (200, 500, 1000 and 2000 patients annually) and we assess the tool’s capabilities with respect to the design of responsive supply chain candidate solutions while minimising cost.

Uncertainty quantification for gene delivery methods: A roadmap for pDNA manufacturing from phase I clinical trials to commercialization

“…Given the company's objectives and resources available, the methodology can be complemented with Mixed Integer Programming (MIP) and multi-objective optimization approaches to assist decisionmakers in the C&GT sector with identifying the most-cost effective and responsive solution. [114,115]…”